Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease, Oncology, and Cardiovascular Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PLA2G2A (Group IIA secretory phospholipase A2) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PLA2G2A (GIIA sPLA2) Recombinant Protein – ECD-Fc / Mutant available High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native folding, disulfide bond formation, and native glycosylation. |
View PLA2G2A Products |
| Gene Delivery | PLA2G2A Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View PLA2G2A Products |
| Benchmark Ab | Anti-PLA2G2A Recombinant Antibody (Sequence of Benchmark) High-affinity sequence-verified positive control for neutralization and detection assays. |
View PLA2G2A Products |
| Validator | PLA2G2A (GIIA sPLA2) siRNA Set Target-specific knockdown verification in cell-based functional assays. |
View PLA2G2A Products |
| Related Target A | PLA2G5 (Group V sPLA2) Homologous sPLA2 isoform. Essential for off-target selectivity screening and cross-reactivity profiling. |
View PLA2G5 Products |
| Related Target B | PLA2G10 (Group X sPLA2) Highly potent homologous sPLA2 involved in inflammatory cascades; crucial counter-screening target. |
View PLA2G10 Products |
| Related Target C | PLA2G1B (Group IB sPLA2) Family member for selectivity counter-screening and cross-reactivity evaluation. |
View PLA2G1B Products |
| Related Target D | COX-2 (PTGS2) Downstream synergistic inflammatory pathway target for combination studies. |
View COX-2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Loss of enzymatic activity / Low baseline activity due to misfolding | HEK293 mammalian expression ensures correct post-translational modifications, native disulfide bond pairing, and native glycosylation. High purity (>95%), ultra-low endotoxin (<1.0 EU/μg). |
| Isoform cross-reactivity / Subfamily counter screening (GIB, GV, GX) | Comprehensive homolog panel (PLA2G5, PLA2G10, PLA2G1B) available with strictly verified sequence purity and mass spec analysis. |
| Lack of reliable positive control | Sequence-verified clinical-grade benchmark neutralizing antibodies (biosimilars) available. |
| In vitro assay background noise / False positives | Validated siRNA included for specificity checks; ultra-low endotoxin levels prevent non-specific immune activation in cell-based assays. |
Live PLA2G2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of PLA2G2A (GIIA sPLA2) is undergoing a major renaissance. Historically recognized as a key biomarker and driver in acute inflammatory conditions such as sepsis, rheumatoid arthritis, and cardiovascular disease, PLA2G2A is now emerging as a critical immune-checkpoint-like target in the tumor microenvironment. Recent studies demonstrate that cancer-cell-derived sPLA2-IIA suppresses T-cell infiltration and promotes immune evasion, shifting the development focus from systemic enzyme inhibitors to localized monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). As first-generation therapies (e.g., Varespladib repurposing by Ophirex) reach the clinic for snakebite envenomation and severe inflammation, the next wave of R&D is targeting highly selective inhibition to avoid off-target effects across the broader phospholipase A2 family. Developers are increasingly focusing on epitope-specific neutralizing antibodies that block the catalytic domain or the interfacial binding site without disrupting physiological lipid homeostasis mediated by other sPLA2 groups.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Ophirex (Varespladib repurposing), Eli Lilly (Historical) | Snakebite Envenomation, Acute Coronary Syndrome, Inflammation | Enzymatic activity profiling and selectivity assay (Requires highly active recombinant protein with low batch variation and high-purity homologs) |
| Monoclonal Antibodies (mAbs) | Academic/Biotech Consortia, Preclinical Biotech | Solid Tumors, Severe Inflammatory Response, COVID-19 ARDS, Rheumatoid Arthritis, Sepsis | Epitope mapping and neutralization assays (Requires native HEK293-expressed PLA2G2A) |
| Bispecific Antibodies | Emerging Oncology Biotechs | Tumor Microenvironment Modulation | Selectivity screening against homologous targets (PLA2G5, PLA2G10) to ensure high safety margins |
| Inhibitory Peptides | Academic Spin-offs | Atherosclerosis | Enzyme inhibition assays (Need native conformation and disulfide integrity) |